NASDAQ:MAZE Maze Therapeutics Q4 2025 Earnings Report $23.86 -0.41 (-1.69%) Closing price 04:00 PM EasternExtended Trading$23.86 0.00 (0.00%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Maze Therapeutics EPS ResultsActual EPS-$0.65Consensus EPS -$0.73Beat/MissBeat by +$0.08One Year Ago EPSN/AMaze Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMaze Therapeutics Announcement DetailsQuarterQ4 2025Date3/25/2026TimeBefore Market OpensConference Call DateTuesday, March 31, 2026Conference Call Time9:30AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Maze Therapeutics Earnings HeadlinesMaze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And RiskJune 13 at 5:45 PM | finance.yahoo.comMaze Therapeutics Shareholders Elect Directors, Ratify AuditorJune 10, 2026 | tipranks.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.June 16 at 1:00 AM | Stansberry Research (Ad)Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?June 6, 2026 | finance.yahoo.comMaze Therapeutics to Participate in Two Upcoming Investor ConferencesMay 27, 2026 | globenewswire.comMaze Therapeutics CFO Expands Role Amid Finance Leadership ChangeMay 22, 2026 | tipranks.comSee More Maze Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Maze Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maze Therapeutics and other key companies, straight to your email. Email Address About Maze TherapeuticsMaze Therapeutics (NASDAQ:MAZE) (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic. Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas. By integrating large‐scale genetic datasets with functional genomics assays, the company seeks to uncover previously unrecognized pathways that can be modulated by small molecules or biologics. Its target selection strategy is designed to deliver higher confidence in clinical proof‐of‐concept studies, and Maze’s research collaborations with academic and industry partners support the advancement of its most promising candidates through preclinical and early clinical stages. Headquartered in South San Francisco, California, Maze Therapeutics operates within a vibrant biotech cluster and draws on a network of scientific advisors and strategic collaborators worldwide. The company is led by a management team with extensive experience in genomics, drug development and translational research. By focusing on genetically validated targets and a disciplined go-to-clinic approach, Maze aims to bring transformative therapies to patients in need while creating value for its shareholders.View Maze Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Okta’s AI Moment May Be Bigger Than Investors RealizeStrategy’s Bitcoin Rally Has a Hidden EngineIs Lennar Finally Turning the Corner After Its Housing Slump?Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?This Golden Cross Could Send Urban Outfitters to New Highs3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big Question Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
